New insider activity at Pulmonx ( (LUNG) ) has taken place on March 6, 2025.
In recent transactions involving Pulmonx stock, CCO Geoffrey Beran Rose sold 5,779 shares, amounting to a total of $41,193. Additionally, SVP & GC David Aaron Lehman sold 8,733 shares, with the sale valued at $62,353.
Recent Updates on LUNG stock
Pulmonx Corporation’s recent financial disclosures and earnings call highlighted significant revenue growth and strategic advancements, despite facing financial challenges. The company reported a 23% year-over-year increase in Q4 2024 revenue, reaching $23.8 million, and a 22% increase for the full year, driven by strong international sales and U.S. market expansion. However, increased operating expenses and net losses tempered these achievements. Pulmonx’s strategic initiatives, including the launch of the AeriSeal CONVERT II Pivotal Trial and new product innovations, underscore its commitment to growth. The company anticipates a 16% to 18% revenue growth in 2025, with stable gross margins, but acknowledges potential risks from foreign exchange fluctuations. These developments have influenced analysts’ perspectives, focusing on Pulmonx’s ability to sustain growth amid market risks.
More about Pulmonx
YTD Price Performance: 32.98%
Average Trading Volume: 320,543
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $345M